{
    "Trade/Device Name(s)": [
        "HER2/ER/PR IHControls\u00ae - Level H",
        "HER2/ER/PR IHControls\u00ae - Level M",
        "HER2/ER/PR IHControls\u00ae - Level L"
    ],
    "Submitter Information": "Boston Cell Standards, Inc.",
    "510(k) Number": "K220163",
    "Predicate Device Reference 510(k) Number(s)": [
        "K023335"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NJW"
    ],
    "Summary Letter Date": "January 10, 2022",
    "Summary Letter Received Date": "January 20, 2022",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.1860"
    ],
    "Regulation Name(s)": [
        "Immunohistochemistry Reagents And Kits"
    ],
    "Analyte Class(es)": [
        "anatomic pathology",
        "misc"
    ],
    "Analyte(s)": [
        "HER2",
        "ER",
        "PR"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed paraffin-embedded (FFPE) breast tumor samples"
    ],
    "Specimen Container(s)": [
        "Microscope slide"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunohistochemistry (IHC)",
        "Antigen retrieval",
        "Immunostaining"
    ],
    "Methodologies": [
        "Qualitative on-slide peptide-based control",
        "Immunoreactivity assessment"
    ],
    "Submission Type(s)": [
        "Control",
        "Reference Material",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for HER2/ER/PR IHControls\u00ae peptide-based qualitative on-slide controls used to monitor immunohistochemical staining process for HER2, ER, and PR in FFPE breast tumor samples",
    "Indications for Use Summary": "Peptide-based qualitative on-slide controls to monitor analytic components of IHC staining for HER2, ER, and PR, indicated for use with FFPE breast tumor samples, not for scoring slides, and not intended to replace approved IHC device controls",
    "fda_folder": "Hematology"
}